Studies of SARS virus vaccines by Zheng, BJ et al.
Title Studies of SARS virus vaccines
Author(s) Zheng, BJ; Du, LY; Zhao, GY; Lin, YP; Sui, HY; Chan, C; Ma, S;Guan, Y; Yuen, KY
Citation Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p. 39-43
Issued Date 2008
URL http://hdl.handle.net/10722/157565
Rights Hong Kong Medical Journal. Copyright © Hong Kong MedicalAssociation.
Hong Kong Med J Vol 14 No 4 Supplement 4 August 2008      39
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES
Department of Microbiology, The 
University of Hong Kong, Pokfulam, Hong 
Kong SAR, China
BJ Zheng, LY Du, GY Zhao, YP Lin, HY Sui, 
C Chan, S Ma, Y Guan, KY Yuen
RFCID project number: 01030292
Principal applicant and corresponding author:
Dr Bojian Zheng
Department of Microbiology, The University 
of Hong Kong, University Pathology Build-
ing, Queen Mary Hospital, Pokfulam Road, 
Hong Kong SAR, China
Tel: (852) 2855 4383
Fax: (852) 2855 1241
E-mail: bzheng@hkucc.hku.hk
Studies of SARS virus vaccines
Key Messages
1. Intranasal vaccination using inactivated 
SARS coronavirus (SARS-CoV) vaccine 
with adjuvant can induce strong systemic 
(serum immunoglobulin [Ig] G) and 
respiratory tract local (tracheal-lung 
wash fluid IgA) antibody responses with 
neutralising activity.
2. RBD-Fc (protein-based vaccine) is able 
to induce effective neutralising antibodies 
able to provide protection from SARS-
CoV infection in animal models.
3. A single dose of RBD-rAAV vaccination 
can induce adequate neutralising antibody 
against SARS-CoV infection.
4. Additional doses of vaccine increased the 
production of neutralising antibody 5 fold 
compared with a single dose.
5. RBD-rAAV vaccination provoked 
a prolonged antibody response with 
continually increasing levels of neutralising 
activity.
6. Intranasal vaccination with RBD-rAAV 
induced local IgA and systemic IgG 
neutralising antibodies and specific T-cell 
responses, able to protect against SARS-
CoV infection in animal models.
7. When compared with the RBD-rAAV 
prime/boost vaccination, RBD-rAAV 
prime/RBD-peptide boost induced similar 
levels of Th1 and neutralising antibody 
responses that protected vaccinated mice 
from subsequent SARS-CoV challenges, 
but stronger Th2 and CTL responses.
8. Overall, our findings suggest that the 
inactivated vaccine, RBD-Fc and RBD-
rAAV, can be further developed into 
effective and safe vaccines against SARS 
and that intranasal vaccination may be the 
preferred route of administration.
Hong Kong Med J 2008;14(Suppl 4):S39-43
Introduction
Although SARS has been under control since June 2003, epidemiologists 
and scientists have predicted that an outbreak may recur in coming years. 
Therefore, development of a vaccine able to prevent SARS remains a high 
priority. This study was designed to investigate the hypothesis that inactivated 
vaccine, protein-based vaccine and rAAV live vaccine may be crucial means of 
preventing SARS. Our objectives were: (1) evaluation of an inactivated vaccine 
candidate, (2) construction and evaluation of an RBD-Fc vaccine candidate, and 
(3) construction and evaluation of an RBD-rAAV vaccine candidate.
Methods
This study was conducted from January 2005 to December 2006.
Study design
Inactivated vaccine
SARS coronavirus (SARS-CoV) strain GZ50 (GenBank accession number AY 
304495) was used for generation of the inactivated vaccine candidate, because 
full-length sequencing and phylogenetic analysis showed that GZ50 lay between 
the reported Hong Kong strains and the Canadian and US strains.1
Protein-based vaccine
The RBD region of SARS-CoV S protein was selected as the target for the 
protein-based vaccine candidate, because it is the major determinant in eliciting 
neutralising antibody against SARS-CoV.2 The RBD was fused with the Fc 
domain of human IgG1 (RBD-Fc), so that the fusion protein could be easily 
purified using a protein A-Sepharose column. Furthermore, the Fc domain of 
the fusion protein was able to bind to the Fc receptors on the surfaces of antigen 
presenting cells (APC) and enhance the immune responses initiated by the 
APC.
AAV-based vaccine
AAV was used as a delivery system for the construction of live vaccine candidates 
based on the following rationale: (1) respiratory and intestinal tracts are natural 
infection sites for both SARS-CoV and AAV; (2) intranasal vaccination of rAAV 
may induce strong local (respiratory tract) and systemic immune responses, 
including neutralising antibody responses; and (3) epithelial cells infected by 
the rAAV will be replaced by new epithelial cells derived from basal cells in the 
respiratory tract within several months, resulting in clearance of rAAV integrated 
cells, hence minimising the long-term risk caused by rAAV DNA integration into 
host chromosome DNA. On the other hand, it has been demonstrated that RBD 
can induce strong neutralising antibodies. We thus constructed RBD-rAAV as a 
vaccine candidate.
Study instruments
Construction and/or preparation of inactivated vaccine, RBD-Fc and 
RBD-rAAV
The vaccine candidates were prepared and/or constructed as described.3-5
Evaluation of immune responses to the vaccine candidates in mouse 
models
Mice were intramuscularly or intranasally immunised with the vaccine candidates. 
Systemic and local immune responses, including antibodies, Th and CTL, were 
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detected by enzyme-linked immunosorbent assays (ELISA), 
neutralisation assays, ELISPOT and triple staining of the 
cell surface and intracellular cytokines were measured by 
flow cytometry as described.3-5
Evaluation of the protective effect of the vaccine 
candidates in SARS-CoV animal models
The protective effects of the vaccine candidates were 
evaluated in SARS-CoV–challenged mice. Viral load 
and pathological changes were tested using virus 
titration, real-time reverse transcription polymerase 
chain reaction, haematoxylin and eosin (H&E) staining 
etc, as described.3-5
Results
Antibody responses in inactivated vaccine–
immunised mice
After two subcutaneous injections of 80 µg of inactivated 
virus, only low titres of ELISA antibody (1:8) were 
detected. Sera from the intranasal vaccination group were 
all negative, but showed neutralising antibody activity. 
Although a lower dosage of virus was used for intranasal 
immunisation of PEG-precipitated inactivated SARS-
CoV, the serum neutralising antibody titre was 1:160 in 
all the mice in this group. When tracheal-lung-wash fluid 
was tested for anti-SARS immunoglobulin (Ig) A by 
immunofluorescence, no positive staining was detected 
in the group immunised with inactivated virus only. 
Nonetheless, strong immunofluorescence staining at 1:5 
dilution was shown in all groups of mice immunised with 
the virus plus the adjuvants, and in mice immunised with 
PEG-inactivated virus.3
Vaccination with RBD-Fc induced long-term and 
potent SARS-CoV S-specific antibodies with strong 
neutralising activity
RBD-Fc vaccination induced a prolonged and potent 
humoral immune response with IgG specific to SARS-CoV 
S protein as tested by ELISA. Highest titres were reached 
during the third and fourth post-vaccination months. 
Although titres decreased slightly afterwards, specific IgG 
antibody levels increased rapidly after the third booster 
dose (12 months after the first vaccination). It was further 
demonstrated that the antibodies induced by vaccination 
with RBD-Fc exhibited a strong neutralising activity 
showing similar patterns to the ELISA antibodies to RBD. 
Furthermore, viral RNA copies for both the RBD-Fc group 
and the control group showed a reverse correlation with 
the titre levels of the neutralising antibodies (Table). These 
results suggest that the neutralisation test induced by RBD-
Fc vaccination plays an important role in the prevention of 
SARS-CoV infection in virus-challenged mice. 4
Mice vaccinated with RBD-Fc did not develop 
histopathological changes in their lung tissues
Histopathological changes in lungs from the RBD-Fc 
vaccinated and control mice were observed using H&E-
stained lung tissue sections. Lung tissues from the control 
mice revealed significant histopathological changes while 
lung tissues from the four RBD-Fc vaccinated mice 
exhibited no significant histopathological changes and 
were the same as normal mouse lung tissues.4 These results 
indicate that RBD-Fc vaccine is able to prevent SARS-CoV 
infection in mice.
A single dose of RBD-rAAV vaccination induced 
adequate SARS-CoV specific antibody responses 
with neutralising activity in mice
After a single dose of RBD-rAAV intramuscular vaccination, 
SARS-CoV specific antibodies in the sera of immunised 
mice reached 1:880 at 4 months post-vaccination. Inactivated 
virus vaccination stimulated antibodies that peaked earlier 
and at a slightly lower level or at a significantly lower level 
(P<0.05) at 2 months post-immunisation. The neutralising 
antibody levels rose continuously from 1:48 at 1 month 
to 1:108 at 4 months post-vaccination with RBD- which 
was similar to the peak level seen in those vaccinated with 
the inactivated virus suspended in Alum at 2 months post-
vaccination, but three-fold higher than those given the 
inactivated virus suspended in PBS (P<0.05). 5
Repeated vaccinations of RBD-rAAV effectively 
induced high levels of SARS-CoV–specific 
antibodies with neutralising activity
In a further experiment, mice were given two further 
doses of RBD-rAAV or inactivated virus intramuscularly. 
In the animals given the RBD-rAAV vaccine, the level of 
the SARS-CoV–specific antibody determined by ELISA 
increased continuously throughout the experiment, reaching 
a titre of 1:5120 at 5.5 months post-vaccination. In animals 
given the inactivated virus, the antibody levels peaked at 
4 months post-vaccination. The neutralising antibody level 
in the RBD-rAAV group of animals also rose continuously 
throughout the 5.5 months of the study. The neutralising 
antibody levels seen in the RBD-rAAV group were similar 
to the peak neutralising antibody levels of those given the 
inactivated virus vaccine but five times higher than those 
induced by a single dose of this vaccine.5
Group Mouse Neutralising 
antibody titres
RNA copies/g of 
lung tissues
RBD-Fc 
vaccination
M1
M2
M3
M4
M5
57
189
505
452
404
3.13x103
Undetectable
Undetectable
Undetectable
Control C1
C2
C3
C4
C5
<4
<4
<4
<4
<4
1.39x107
3.77x107
1.39x105
1.98x106
1.45x106
Table.	 SARS	coronavirus	RNA	copies	in	lung	tissue,	
measured	by	Q-reverse	transcription	polymerase	chain	
reaction
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Intranasal vaccination induced a shorter-duration 
systemic humoral immune response but a stronger 
and prolonged mucosal immunoglobulin A response 
than intramuscular vaccination
A single-prime dose of intranasal vaccination of RBD-
rAAV did not induce a significant antibody response. After 
a booster dose, the vaccine rapidly stimulated a strong IgG 
antibody response, reaching its highest titre 1 month post-
vaccination but the IgG antibody level dropped to a low level 
one month later. The neutralising antibody levels followed 
a similar pattern. These results indicate that intranasal 
vaccination induces similar neutralising antibody levels but 
shorter-duration systemic humoral immune responses than 
intramuscular immunisation.6
 Mucosal IgA SARS-CoV–specific antibody was further 
detected in the lung flush of vaccinated mice. RBD-rAAV 
intranasal prime-boost induced a strong IgA antibody 
response, which was significantly higher than that elicited 
intramuscularly by RBD-rAAV with a single-prime dose 
and prime-boost doses, respectively (Fig 1a). The IgA 
antibody titres and neutralising antibodies induced by the 
RBD-rAAV intranasal prime-boost in the mouse lung flush 
were further analysed at 0.5-month intervals. It was shown 
that the mucosal IgA antibody level reached its peak at 1 
month post-vaccination, and gradually decreased to a low 
level in the following 5 months (Fig 1b). The lung flush 
from RBD-rAAV intranasal prime-boost vaccinated mice 
contained high-level and long-lasting neutralising antibody 
against SARS-CoV, which was highly detectable during 
the 6-month monitoring period (Fig 1c). The data indicated 
that intranasal vaccination with RBD-rAAV induced a long-
term mucosal immune response with neutralising activity, 
implying that mucosal vaccination with RBD-rAAV should 
provide an effective protective immune response against 
SARS-CoV.6
Intranasal vaccination induced strong CTL 
responses in spleen and lungs
The CTL responses induced by RBD-rAAV vaccination 
were examined by measuring splenocytes and lung 
lymphocytes using ELISPOT and FACS. The intranasal 
vaccination with RBD-rAAV induced a markedly higher 
level of antigen specific IL-2+ T cells but a slightly lower 
level of IFN-γ+ T cells in the spleen. Specific CTL responses 
induced by RBD-rAAV vaccinations were further evaluated 
in the mouse splenocytes and lung lymphocytes using 
cell surface markers and intracellular cytokine staining 
followed by FACS. RBD-rAAV intranasal vaccination 
induced a markedly higher frequency of IL-2+ cells in the 
CD3+/CD8+ T cell population in both splenocytes and lung 
cells. In addition, IFN-γ-producing CD3+/CD8+ T cells 
were significantly higher in the splenocytes of RBD-rAAV 
intranasally versus intramuscularly vaccinated mice, but 
were similar or slightly lower in the lung lymphocytes from 
intranasally versus intramuscularly immunised mice.6
RBD-rAAV vaccination suppressed SARS-CoV 
replication in mouse lungs
The vaccine protective efficacies were further investigated 
in mice challenged with 105 TCID50 of SARS-CoV strain 
GZ50. Viral loads (RNA copies/µg of lung tissues) in all 
mice immunised with RBD-rAAV were significantly lower 
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Fig	1.	Local	humoral	immune	response	to	RBD-rAAV	
vaccinations
(a) Comparison of mucosal IgA in intramuscularly and intranasally 
vaccinated mice. (b) Monitoring of mucosal IgA antibody levels 
in mice intranasally vaccinated with RBD-rAAV. (c) Detection of 
neutralising antibody titres in lung flush of intranasally vaccinated 
mice6
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than those in the corresponding control group immunised 
with blank AAV via intramuscular and intranasal routes 
(P<0.05). This indicates that SARS-CoV replication was 
effectively suppressed in the vaccinated mice.6
RBD-rAAV vaccination provided long-term 
protection against SARS-CoV challenge
Mice were given RBD-rAAV booster doses 12 months after 
the first RBD-rAAV immunisation, and challenged with 105 
TCID50 of SARS-CoV. Challenged mice were sacrificed 
8 days post-challenge and examined for histopathological 
changes. Serious pulmonary interstitial pneumonias were 
observed in the lung tissues of all control mice vaccinated 
with blank AAV after the SARS-CoV challenge (Fig 2a). In 
contrast, the mice vaccinated with RBD-rAAV showed no 
significant pulmonary effects after the viral challenge (Fig 
2b). These results demonstrate that RBD-rAAV vaccinations 
provide long-term protective immunity against SARS-CoV 
infection in mice. 6
Priming with RBD-rAAV and boosting with RBD-
specific peptides elevated humoral and cellular 
immune responses against SARS-CoV infection
The immune responses to and protective effects of the 
immunisation with RBD-rAAV prime/RBD-specific T 
cell peptide boost were further evaluated. Compared with 
the RBD-rAAV prime/boost vaccination, the RBD-rAAV 
prime/RBD-peptide boost induced similar levels of Th1 
and neutralising antibody responses that protected the 
vaccinated mice from subsequent SARS-CoV challenges, 
but stronger Th2 and CTL responses. 7 Since T cell epitopes 
are highly conserved and boosting with peptides may induce 
the production of effector memory T cells, which may be 
effective against viruses with mutations in the neutralising 
epitopes, these results suggest that the vaccination protocol 
used may be ideal for providing effective, broad and long-
term protection against SARS-CoV infection.7
Conclusion
This study has shown that inactivated vaccine candidates, 
RBD-Fc, RBD-rAAV and T cell specific peptides, have 
the potential to be further developed into safe and effective 
vaccines able to prevent SARS-CoV infection. It has also 
shown that intranasal vaccination may be the preferred 
route of administration.
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Fig	2.	Histopathology	of	mouse	lungs	infected	with	severe	acute	respiratory	syndrome	coronavirus	8	days’	post-infection6
All sections of mouse lung tissue were examined under the microscope (H&E, x100). (a) Representative images of histopathological 
damage to lung tissue from control mice given blank AAV in either intramuscular (C1-C2) or intranasal (C3-C4) booster vaccinations. 
These control mice developed interstitial pneumonia. Infiltrating lymphocytes and mononuclear cells were identified around small 
blood vessels (white arrows). Pulmonary vascular peripheral lymphocyte infiltration was also seen, with bronchial epithelial cell 
degeneration, necrosis, desquamation (black arrows), broadening interstitial spaces, and exudates. (b) Representative images of 
the histopathological changes in lung tissue from mice intramuscularly vaccinated with a single-prime dose (M1) or prime-booster 
doses (M2), and intranasally vaccinated with prime-booster doses (M3-M4) of RBD-rAAV. The lung tissue from single-prime dose 
intramuscularly vaccinated mice shows mild interstitial pneumonia changes with focal broadening of the interstitial spaces and 
lymphocytic infiltration (arrowhead) [M1]. Mice given intramuscular prime-booster vaccinations developed slight interstitial pneumonia 
with normal alveolae, slightly widened pulmonary intervals and small lymphocytic infiltrations (arrowhead) [M2]. Mice given intranasal 
prime-boost vaccinations showed almost normal vascular structures, bronchioles, alveolae, and alveolar lung spacing (M3-M4)
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virus encoding receptor-binding domain of severe acute 
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